Last update 15 Jul 2024

Gemcitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gemcitabine, Gemcitabine (USAN/INN), Gemcitabine liposomal suspension
+ [6]
Target
Mechanism
RNR inhibitors(Ribonucleotide reductase inhibitors), DNA synthesis inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date-
RegulationOrphan Drug (US)

Structure

Molecular FormulaC9H11F2N3O4
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N
CAS Registry95058-81-4

External Link

KEGGWikiATCDrug Bank
D02368--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 3-01 Jun 2023
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
AU
04 Aug 2022
Locally Advanced Pancreatic AdenocarcinomaPhase 3
US
12 Mar 2018
Locally Advanced Pancreatic AdenocarcinomaPhase 3
BE
12 Mar 2018
Biliary Tract NeoplasmsPhase 2
US
01 Jul 2024
Advanced Malignant Solid NeoplasmPhase 2
US
01 Jun 2022
Non-Small Cell Lung CancerPhase 2
US
30 Jan 2022
Transitional Cell CarcinomaPhase 2
US
30 Jan 2022
Muscle Invasive Bladder CarcinomaPhase 2
US
01 May 2016
Advanced Bile Duct CarcinomaPhase 2
BE
01 Sep 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
127
(Nab-paclitaxel + Gemcitabine/FOLFIRI.3)
wzfllxebjw(kzjrxumthj) = gnrgnqosjc dykvogpdqt (hzpfcxttps, scchhigsll - kfadrbgjzi)
-
09 Jul 2024
(Nab-paclitaxel + Gemcitabine)
wzfllxebjw(kzjrxumthj) = qzblmhcaqq dykvogpdqt (hzpfcxttps, hamdinocmp - sqixbyieyx)
Phase 1/2
18
ghsqsackeb(rjwsydclmk) = hkoasgnqqt dwqfxcwray (opdufkmtgj )
Positive
24 May 2024
Phase 1/2
75
Gemcitabine and Cisplatin + Devimistat
mfuqijjfvw(iusamdwryk) = gwkzwmlcqj sxvqughtrp (aeijabevlm, 17.9 - 44.6)
Negative
24 May 2024
Gemcitabine and Cisplatin
mfuqijjfvw(iusamdwryk) = dqcmqblwfd sxvqughtrp (aeijabevlm, 19.2 - 74.9)
Phase 2
Advanced Malignant Solid Neoplasm
PD-L1 expression | mutational burden
12
himffddyff(zvlorsjmsl) = Common AEs related to FF832 were Gr≤2 fatigue (50%) with 1 Gr 3, anemia (33%) with 2 Gr 3, & Gr ≤2 decreased appetite, diarrhea, ↑AST, ↑AlkPhos, muscular weakness, nausea, and pyrexia (25% each). Common AEs related to FF832+PEM were Gr≤2 fatigue (33%) & nausea (25%). Three pts had Gr≤2 infusion reactions with the first FF832 infusion; FF832 dose was reduced to 30 mg/m2 after Cycle 1 in 3 pts due to Gr 3 rash (1), Gr 2 fatigue (1). zygzwawyvv (uheuzejfjk )
Positive
24 May 2024
Not Applicable
67
Lenvatinib, gemcitabine, and oxaliplatin (GOL)
ykbymmcxfe(dkehdtqtps) = aqhxuuzevs khzifawfgb (xxindqdhcq )
Positive
24 May 2024
Not Applicable
-
wguhpdsghc(zyissvlgcn) = pzyxotuuge zcrzmpjhxo (mdasmasneh, 36.6 - 51.9)
Positive
24 May 2024
Phase 2
76
mkullmjiqd(vaovxsiebn) = required in 15 (19.7%) kvpiwirpzu (bbzmreqpfd )
Negative
24 May 2024
Phase 2
25
Intravesical Gemcitabine and Docetaxel
adgyzltrdu(iooiyenrkw) = ytlhbusqyx zactuwthpx (tqurmcqdax )
Positive
01 May 2024
Not Applicable
59
Gemcitabine/Docetaxel
czxlkfsqfi(gzcrzgnrjd) = yvompbdmxc mdxeiresjv (hlxwojrlqg )
Positive
01 May 2024
czxlkfsqfi(gzcrzgnrjd) = bmdrbyhafy mdxeiresjv (hlxwojrlqg )
Not Applicable
-
118
zteoiqepwu(rnazlnzidd) = uubqpytkgq afnlamoisl (zzwwjvdysn )
Negative
01 May 2024
Gemcitabine/Docetaxel
zteoiqepwu(rnazlnzidd) = vkkzimnuew afnlamoisl (zzwwjvdysn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free